Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg.

Literature DB >> 15596777

Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg.

Stephan J Rüegg¹, Peter Fuhr, Andreas J Steck.

Abstract

The authors report a patient with anti-GM(1) antibody-negative multifocal motor neuropathy (MMN) who was increasingly less responsive to IV immunoglobulins (IVIgs). Five yearly courses of the monoclonal anti-CD20 antibody rituximab were well tolerated and extended the interval of IVIg administration from 7 to 12 days (corresponding to 42% reduction of IVIg) during this period. Rituximab may be a benefit for patients with MMN.

Entities: Chemical Gene Species

Mesh：

Substances：

Year: 2004 PMID： 15596777 DOI： 10.1212/01.wnl.0000145706.04340.25

Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910

Keyword Cloud
Cited

21 in total

Review 1. Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies.

Authors: Lotte Vlam; W-Ludo van der Pol; Elisabeth A Cats; Dirk C Straver; Sanneke Piepers; Hessel Franssen; Leonard H van den Berg
Journal: Nat Rev Neurol Date: 2011-11-22 Impact factor: 42.937

Review 2. [Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: update 2010].

Authors: M Stangel; R Gold
Journal: Nervenarzt Date: 2011-04 Impact factor: 1.214

3. Pathogenesis and treatment of immune-mediated neuropathies.

Authors: Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal: Ther Adv Neurol Disord Date: 2009-07 Impact factor: 6.570

4. Practical considerations on the use of rituximab in autoimmune neurological disorders.

Authors: Mixalis L Kosmidis; Marinos C Dalakas
Journal: Ther Adv Neurol Disord Date: 2010-03 Impact factor: 6.570

Review 5. Therapy of immune neuropathies with intravenous immunoglobulins.

Authors: Ralf Gold; Bernd C Kieseier
Journal: J Neurol Date: 2006-09 Impact factor: 4.849

6. Guillain-Barre syndrome in a patient with diffuse large B-cell lymphoma, and rituximab maintenance therapy. An association beyond anecdotal evidence?

Authors: Alberto Carmona; Juan Domingo Alonso; Manuel de las Heras; Agustín Navarrete
Journal: Clin Transl Oncol Date: 2006-10 Impact factor: 3.405

Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg.

Review 1. Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies.

Review 2. [Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: update 2010].

3. Pathogenesis and treatment of immune-mediated neuropathies.

4. Practical considerations on the use of rituximab in autoimmune neurological disorders.

Review 5. Therapy of immune neuropathies with intravenous immunoglobulins.

6. Guillain-Barre syndrome in a patient with diffuse large B-cell lymphoma, and rituximab maintenance therapy. An association beyond anecdotal evidence?

7. Diagnosis and treatment of multifocal motor neuropathy.

Review 8. Molecularly targeted therapies for dysimmune neuropathies.

9. Safety and efficacy of CAR T cells in a patient with lymphoma and a coexisting autoimmune neuropathy.

Review 10. [Rituximab in treatment for neuroimmunological diseases].